- Home
- MRT vs FENC Comparison
MRT vs FENC Comparison
Compare MRT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- FENC
- Stock Information
- Founded
- MRT 2018
- FENC 1996
- Country
- MRT Turkey
- FENC United States
- Employees
- MRT N/A
- FENC 32
- Industry
- MRT Rental/Leasing Companies
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRT Consumer Discretionary
- FENC Health Care
- Exchange
- MRT Nasdaq
- FENC Nasdaq
- Market Cap
- MRT 228.0M
- FENC 234.9M
- IPO Year
- MRT N/A
- FENC 2001
- Fundamental
- Price
- MRT $2.29
- FENC $8.28
- Analyst Decision
- MRT Strong Buy
- FENC Strong Buy
- Analyst Count
- MRT 2
- FENC 2
- Target Price
- MRT $6.00
- FENC $13.50
- AVG Volume (30 Days)
- MRT 188.1K
- FENC 97.6K
- Earning Date
- MRT 01-01-0001
- FENC 11-06-2025
- Dividend Yield
- MRT N/A
- FENC N/A
- EPS Growth
- MRT N/A
- FENC N/A
- EPS
- MRT N/A
- FENC N/A
- Revenue
- MRT $24,577,378.00
- FENC $33,302,000.00
- Revenue This Year
- MRT $84.11
- FENC $0.18
- Revenue Next Year
- MRT $125.86
- FENC $52.59
- P/E Ratio
- MRT N/A
- FENC N/A
- Revenue Growth
- MRT 29.67
- FENC N/A
- 52 Week Low
- MRT $1.81
- FENC $3.96
- 52 Week High
- MRT $3.89
- FENC $9.92
- Technical
- Relative Strength Index (RSI)
- MRT 46.38
- FENC 38.45
- Support Level
- MRT $2.16
- FENC $9.19
- Resistance Level
- MRT $2.46
- FENC $9.92
- Average True Range (ATR)
- MRT 0.15
- FENC 0.37
- MACD
- MRT 0.01
- FENC -0.13
- Stochastic Oscillator
- MRT 64.00
- FENC 2.34
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.